Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

Summary

This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a ratio of 1:1:1 , HDM1005 or placebo will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

Timeline

Start

2025-10-14

Primary completion

2026-09-20

Completion

2026-12-13

Drugs

Indications